Cipla Ltd has received an approval for its product Q-TIB from World Health Organization (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.
Q-TIB will help prevent tuberculosis infection in people living with HIV who face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them.